Hepatitis B Hepatitis B  Sustained e antigen loss after treatment is ~45% in types A and B but only 25â€“30% in types C and D. It seems unlikely that the disease will be eliminated by 2030, the goal set in 2016 by WHO.  However, progress is being made in developing therapeutic treatments.  In 2010, the Hepatitis B Foundation reported that 3 preclinical and 11 clinical-stage drugs were under development, based on largely similar mechanisms.  In 2020, they reported that there were 17 preclinical- and 32 clinical-stage drugs under development, using diverse mechanisms. Hepatitis B virus infection may be either acute  or chronic .  Persons with self-limiting infection clear the infection spontaneously within weeks to months Hepatitis B Hepatitis B